Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
s7wNtvpSzRzTXCSb
Listen
